Detalles de la búsqueda
1.
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Br J Clin Pharmacol
; 87(4): 1824-1838, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32986868
2.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Lancet
; 394(10198): 576-586, 2019 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31280967
3.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 376(16): 1551-1560, 2017 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28423301
4.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
J Allergy Clin Immunol
; 143(6): 2158-2169, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578873
5.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30097359
6.
The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
Clin Pharmacol Drug Dev
; 13(2): 197-207, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37960990
7.
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357.
CPT Pharmacometrics Syst Pharmacol
; 12(6): 758-769, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36919398
8.
Treatment with a novel topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores.
J Drugs Dermatol
; 11(8): 970-7, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22859243
9.
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.
Dermatol Ther (Heidelb)
; 11(2): 487-497, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512666
10.
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists.
Dermatol Ther (Heidelb)
; 11(2): 529-541, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33638115
11.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
JAMA Dermatol
; 156(6): 649-658, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32267471
12.
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
J Dermatol
; 46(8): 686-694, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31237727
Resultados
1 -
12
de 12
1
Próxima >
>>